Company intelligence
Acadia Pharmaceuticals
About Acadia Pharmaceuticals
At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.
Verified activity
Signals from Acadia Pharmaceuticals
5 published signals
People
Acadia Pharmaceuticals supported Lambros Chrones, MD, by passing the first course of the Medical Statistics Program.
Reported by Lambros Chrones, MD
Presence & Recognition
Acadia Pharmaceuticals is hosting an Rett-Ventures event at the YMCA of Columbia-Willamette on Saturday, September 12, 2026, featuring swimming, arts and crafts, and connection.
Reported by Acadia Pharmaceuticals
Presence & Recognition
Acadia Pharmaceuticals was recognized by Newsweek for its workplace culture.
Reported by Clancy Smith
Presence & Recognition
Acadia Pharmaceuticals was recognized by Newsweek for employee experience, inclusion, wellbeing, development, and belonging.
Reported by Nancy Vance
Research & Knowledge
Acadia Pharmaceuticals published a Perspectives article by Michele Scaliti and Matt Jaco discussing the engagement and special place to be in the LTC market and pharmacy market.
Reported by Acadia Pharmaceuticals